Who are PF-07852352 Influenza saRNA 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PF-07914705 Influenza saRNA, Assorted Licensed Hand Sanitizer Grape 01, Prepandrix™, PF-07915048 Influenza saRNA, Quadrivalent influenza modRNA vaccine, Qiv.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-07852352-influenza-sarna-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

PF-07852352 Influenza saRNA 1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-07852352 Influenza saRNA 1 (pf-07852352-influenza-sarna-1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antisense oligonucleotide. Area: Infectious Disease.

marketed antisense oligonucleotide influenza virus Infectious Disease Live · refreshed every 30 min

Target snapshot

PF-07852352 Influenza saRNA 1 (pf-07852352-influenza-sarna-1) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PF-07852352 Influenza saRNA 1 TARGET	pf-07852352-influenza-sarna-1	Pfizer	marketed	antisense oligonucleotide	influenza virus
PF-07914705 Influenza saRNA	pf-07914705-influenza-sarna	Pfizer	marketed	RNA-based therapy	influenza virus
Assorted Licensed Hand Sanitizer Grape 01	Licensed Influenza Vaccine 3	BioNTech	marketed	Vaccine	Influenza virus hemagglutinin protein
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
PF-07915048 Influenza saRNA	pf-07915048-influenza-sarna	Pfizer	marketed	RNA-based therapy	influenza virus
Quadrivalent influenza modRNA vaccine	quadrivalent-influenza-modrna-vaccine	Pfizer	marketed	Vaccine	Influenza virus
Qiv	qiv	Pfizer	marketed	Inactivated vaccine	Influenza viruses

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antisense oligonucleotide class)

Acerta Pharma BV · 1 drug in this class
Avidity Biosciences, Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Ionis Pharmaceuticals, Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Supernus Pharmaceuticals, Inc. · 1 drug in this class
Sylentis, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-07852352 Influenza saRNA 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07852352-influenza-sarna-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab